1.Effect of Plasma and Serum Containing Danshen Injection on Angiogenesis
Traditional Chinese Drug Research & Clinical Pharmacology 2000;0(06):-
Objective To compare with the different effect of the plasma and serum containing Danshen Injection (DI) on the angiogenesis. Methods The DI-containing plasma and serum at different concentrations and sampled at different time were prepared. The effect of DI-containing plasma and serum on the angiogenesis of chicken chorioallantoic membrane (CAM) was observed by using CAM model. Results The proliferation of vessels in all DI-containing plasms and serum groups and DI group was obvious as compared with that in the group of the blank plasma and serum(P
2.Effect and Mechanism of Zacopride on Vasodilatation of Isolated Coronary Arterial Rings in Experimental Rats
Chengfang LIU ; Jin WANG ; Yu LIU ; Rongli HE ; Weiguo ZHANG ; Longgang NIU ; Bowei WU
Chinese Circulation Journal 2015;(12):1212-1215
Objective: To investigate the effect with its possible mechanisms of zacopride on vasodilatation of isolated coronary arterial rings in experimental rats.
Methods: The tension of vasodilatation of isolated coronary arterial rings of male SD rats was recorded by Powerlab and DMT system. The rats were divided into 4 groups: +Endo (vehicle) group, +Endo (zacopride) group and -Endo (vehicle) group, –Endo (zacopride) group.n=6 in each group. The vasodilatation effects of zacopride on KCl (60 mmol/L) and U46619 (10-6 mol/L) pre-constricted arterial ring were recorded; the effects of different agents on zacopride caused vasodilatation were studied.
Results: In both +Endo (zacopride) and –Endo (zacopride) groups, zacopride showed a dose dependent vasodilatation effect on coronary ring pre-constricted by KCl and U46619. The maximum vasodilatation effect of zacopride in KCl treated+Endo (zacopride) group was (90.15 ± 6.38) %, in U46619 treated-Endo (zacopride) group was (81.67 ± 4.97 ) %; the maximum vasodilatation effect of zacopride in KCl treated-Endo (zacopride) group was (85.48±5.04) %, in U46619 treated–Endo (zacopride) group was (79.65 ± 3.51) %, compared to each corresponding vehicle group, allP<0.05. The inhibitor of IK1 channel, BaCl2 could signiifcantly reduce the vasodilatation effect of zacopride in KCl and U46619 pre-constricted coronary ring,P<0.05. However, the inhibitor of eNOS (L-NAME), the blocker of KCa channel (TEA), blocker of Kv channel (4-AP) and blocker of KATP channel (Glib) had no such signiifcant effects, allP>0.05.
Conclusion: Zacopride had vasodilatation effect on coronary arterial ring which was pre-constricted by KCl and U46619, which might be related to the channel of IK1.
3.Clinical analysis of craniocerebral trauma complicated with thoracoabdominal injuries in 2165 cases.
Wei-qun CHEN ; Gang WANG ; Wan ZHAO ; Liang-zhen HE
Chinese Journal of Traumatology 2004;7(3):184-187
OBJECTIVETo explore the optimal treatment for craniocerebral trauma complicated with thoraco-abdominal injuries.
METHODSA total of 2165 cases of craniocerebral trauma complicated with thoraco-abdominal injuries admitted to our hospital between July 1993 and June 2003 were retrospectively studied. Among them, 382 cases sustained severe craniocerebral trauma (in which 167 were complicated with shock), 733 thoracic injuries, 645 abdominal injuries and 787 thoraco-abdominal injuries. On admittance, 294 cases had developed shock. With the prime goal of saving life, respiratory and circulatory systems and encephalothilipsis were especially treated and monitored. Priority in management was directed to severe or open injures rather than to moderate or closed injures. For cases with cerebral hernia due to intracranial hematoma and severe shock due to blood loss, cerebral hernia and shock were treated concurrently.
RESULTSAfter treatment, 2024 (93.49%) cases survived and the other 141 (6.51%) died. Among patients who had severe craniocerebral injury with shock and those without, 78 (46.71%) and 53 (24.56%) died, respectively. For patients who had underwent craniocerebral and thoraco-abdominal operations concurrently and those who had not, the death rates were 58.49%-65.96% and 28.57% respectively, indicating a significant difference (P<0.05).
CONCLUSIONSTreatment for hematoma hernia, shock and disturbed respiration is the key in the management of multiple trauma of craniocerebral, thoracic or abdominal injuries, especially when two or three conditions occurred simultaneously. Unless it is necessary, operations at two different parts at the same time is not recommended. It is preferred to start two concurrent operations at different time.
Adult ; Craniocerebral Trauma ; surgery ; therapy ; Encephalocele ; etiology ; therapy ; Female ; Humans ; Male ; Multiple Trauma ; surgery ; therapy ; Retrospective Studies ; Shock, Hemorrhagic ; etiology ; therapy ; Thoracic Injuries ; surgery ; therapy
4.Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome.
Yu-mei LUO ; Xin-hong WAN ; De-qian JIANG ; Wen-yong KUANG ; Hong-bo GUO ; Zhao-xia CHEN ; He-jin WANG ; Li-hua XIE ; Wen DUAN
Chinese Journal of Cardiology 2009;37(8):739-745
OBJECTIVECoronary arterial plaque rupture and secondary thrombosis are the major pathogenesis of acute coronary syndrome (ACS). Metalloprotease (MMPs) secreted by monocyte/macrophage was the main predisposing factor of the plaque rupture and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is involved in a variety of inflammatory cytokine gene transcriptional regulations. We explored the possible role of PPAR-gamma in the regulation of MMP-9 and TIMP-1 expressed by peripheral monocyte-derived macrophages (MDMs) from patients with ACS.
METHODSPeripheral blood mononuclear cells were isolated from 48 patients with ACS and 28 healthy controls and stimulated by macrophage colony-stimulating factor (0.1 microg/ml for 24 hours) to form MDMs. MDMs were then incubated under various concentrations of rosiglitazone (0, 1, 10, 20 micromol/L) for 48 hours. The concentrations of MMP-9 and TIMP-1 in the supernatant were measured by enzyme linked immunosorbent assay, and the mRNA expression of PPAR-gamma, MMP-9 by RT-PCR and nuclear factor-kappaB P65 (NF-kappaB P65) expression by immunohistochemistry.
RESULTSPPAR-gamma mRNA expression was significantly lower while NF-kappaB P65 and MMP-9 expression as well as MMP-9 and TIMP-1 concentrations in supernatant were significantly higher in ACS group than those in control group (all P < 0.05). After rosiglitazone intervention, PPAR-gamma mRNA expression was significantly upregulated in both ACS and control groups in a dose-dependent manner. Both the MMP-9 concentration in the supernatant and MMP-9 mRNA expression were reduced post intervention with rosiglitazone in both groups. The TIMP-1 mRNA expression and concentration in supernatant were not affected by rosiglitazone in both groups. Rosiglitazone induced significant downregulation of NF-kappaB P65 expression in both groups.
CONCLUSIONRosiglitazone intervention may downregulate MMP-9 expression by upregulating PPAR-gamma expression, and by downregulating NF-kappaB expression in MDMs isolated from patients with ACS.
Acute Coronary Syndrome ; blood ; Aged ; Case-Control Studies ; Cells, Cultured ; Female ; Humans ; Macrophages ; metabolism ; Male ; Matrix Metalloproteinase 9 ; metabolism ; Middle Aged ; PPAR gamma ; agonists ; Thiazolidinediones ; pharmacology ; Tissue Inhibitor of Metalloproteinase-1 ; metabolism ; Transcription Factor RelA ; metabolism ; Vasodilator Agents ; pharmacology